AT-101 is under clinical development by Abclon and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase II drugs for Mantle Cell Lymphoma have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AT-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AT-101 overview

AT-101 is under development for the treatment of blood cancers like B cell leukemia, relapsed or refractory CD19 positive acute lymphoblastic leukemia, lymphoma, relapsed or refractory B-cell non-Hodgkin's lymphoma including diffuse large b-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone b-cell lymphoma. The drug candidate comprises of CD19-CAR -T cells coupled with CD19 antibody. It is administered through intravenous route. It is being developed based on Novel Epitope Screening Technology (NEST).

Abclon overview

Abclon is a biotechnology company that offers drug development and manufacturing services. It discover and develops antibody drugs for the treatment of stomach and lung cancer. Abclon is headquartered in Seoul, South Korea.

For a complete picture of AT-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.